首页 | 本学科首页   官方微博 | 高级检索  
     

匹多莫德对儿童反复呼吸道感染的疗效及对患儿免疫功能的影响
引用本文:周林妫,阎云芸. 匹多莫德对儿童反复呼吸道感染的疗效及对患儿免疫功能的影响[J]. 儿科药学杂志, 2014, 0(3): 33-35
作者姓名:周林妫  阎云芸
作者单位:[1]浙江省丽水市庆元县人民医院,浙江丽水323800 [2]浙江省丽水市中心医院,浙江丽水323000
摘    要:目的:探讨匹多莫德对儿童反复呼吸道感染的疗效及对患儿免疫功能的影响。方法:将120例反复呼吸道感染患儿按随机数字表法分为匹多莫德组和对照组各60例。两组均予以抗感染、退热、止咳化痰等常规治疗,匹多莫德组加用匹多莫德颗粒每次0.4g,每天2次,连用2周,后改为每天1次,疗程共2个月。观察两组患儿治疗前后血清免疫球蛋白IgG、IgA、IgM及T淋巴细胞亚群CD3+、CD4+、CD8+水平的变化,并比较两组治疗效果及不良反应。结果:(1)治疗2个月后,两组患儿的IgG、IgA、IgM及CD3+、CD4+、CD8+水平均较治疗前改善(P〈0.05或P〈0.01),且匹多莫德组改善幅度大于对照组(P〈0.05或P〈0.01);(2)匹多莫德组总有效率高于对照组(91.7%vs78.3%,P〈0.05);(3)两组治疗过程中均未出现明显药物不良反应。结论:匹多莫德治疗儿童反复呼吸道感染疗效确切、安全性佳,能有效改善患儿免疫功能,是一种安全有效的辅助治疗方法。

关 键 词:匹多莫德  反复呼吸道感染  免疫功能

Curative Effect of Pidotimod on Children with Recurrent Respiratory Tract Infection and Its Influence on Immune Function
Zhou Linwei,Yan Yunyun. Curative Effect of Pidotimod on Children with Recurrent Respiratory Tract Infection and Its Influence on Immune Function[J]. Journal of Pediatric Pharmacy, 2014, 0(3): 33-35
Authors:Zhou Linwei  Yan Yunyun
Affiliation:1. Qingyuan People's Hospital of Lishui, Zhejiang Province, Zhejiang Lishui 323000, China; 2. Lishui Central Hospital of Zhejaing Province, Zhejiang Lishui 323000, China)
Abstract:Objective: To discuss curative effect of pidotimod on children with recurrent respiratory tract infection (RRTI) and its influence on immune function. Methods: One hundred and twenty cases of children with RRTI were divided into a Pidotimod group and a control group randomly. The children in the two groups were given routine medical treatment such as anti-lnfection, defervescence, relieving cough and reducing sputum. Children in the pidotimod group were additionally given 0.4 g pidotimod, twice a day for two weeks, then 0.4 g once a day for two months. The changes of IgG, IgA and IgM of serum immune globulins and CD3+, CD4+ and CD8+ of T lymphocyte subsets of children in the two groups before and after medical treatment were observed, and the curative effect and adverse reaction were compared as well. Results: After two months' medical treatment, the IgG, IgA, IgM and CD3+, CD4+, CD8+levels of children in the two groups were obviously improved ( P〈0.05 or P〈0.01 ), and the improvement rate in the pidotimod group was much better than that in the control group (P〈0.05 or P〈0.01 ). Meanwhile, the total clinical efficiency in the pidotimod group was much better than that in the control group (P〈0.05). No obvious adverse drug reaction (ADR) in the two groups was observed during the medical treatment. Conclusions: Pidotimod has reliable curative effect and high security on children with recurrent respiratory tract infection (RRTI) and it can effectively improve the immune function, which is a safe and effective treatment.
Keywords:Pidotimod  Recurrent respiratory tract infection  Immune function
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号